Drug profile

The FDA adverse-event record for Torbugesic

47 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Torbugesic. Species, reactions, and outcomes follow.

#1165 of 2,679
by report volume (all drugs)
47
adverse-event reports
12.8%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Torbugesic ranks #1156 of 2679 by total reports (47). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1156
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Torbugesic has 47 reports now versus 47 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Torbugesic changes

Signature read: death-coded report count at 6 is the most distinctive stamp on Torbugesic's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
47
Total Reports
6
Deaths Reported
12.8%
Death-coded share of reports

Active Ingredients

Torbugesic

Administration Routes

UnknownIntramuscularSubcutaneousIntravenousOralParenteral

Species Affected

Dog 34
Cat 6
Horse 6
Rat 1

Most Affected Breeds

Domestic Shorthair 5
Retriever - Labrador 5
Quarter Horse 3
Shepherd Dog - German 3
Dog (unknown) 3
Retriever - Golden 2
Terrier - Bull - Staffordshire 2
Horse (other) 2
Bichon Frise 2
Retriever (unspecified) 1

Most Reported Reactions

Polydipsia 7
Anorexia 7
Lack of efficacy - NOS 7
Polyuria 6
Other abnormal test result NOS 5
Vomiting 5
Ataxia 5
Elevated blood urea nitrogen (BUN) 4
Elevated creatinine 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Weight loss 3
Restlessness 3

Outcome Breakdown

Recovered/Normal
27 (57.4%)
Outcome Unknown
12 (25.5%)
Euthanized
3 (6.4%)
Died
3 (6.4%)
Ongoing
2 (4.3%)

Torbugesic Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Torbugesic (#1165 of 2,679 by report volume); death-coded 12.8%. PlainBreed drug row · death-coded report count stamp 6 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →